Category: Replacement Heart ValvesSyndicate content

Heart Valves

Press Release: Sorin Group announces CE Mark approval for Crown PRT heart valve

July 25, 2014 by MassDevice

New stented aortic bioprosthesis delivers outstanding implantability and performance.

Press Release: Sorin Group announces CE Mark approval for Crown PRT heart valve

Milan, Italy – Sorin Group, (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced today it has been granted CE mark certification for its innovative stented aortic bioprosthesis Crown PRT, now commercially available in Europe.

Sorin touts E.U. approval for next-gen heart valve

July 25, 2014 by Arezu Sarvestani

Italian device maker Sorin Group lands European regulatory approval for its next-generation Crown PRT replacement aortic heart valve.

Sorin touts E.U. approval for next-gen heart valve

Sorin Group (BIT:SRN) announced this week that it landed European CE Mark approval for its latest aortic heart valve, the Crown PRT.

Press Release: Boston Scientific receives CE Mark for the new 25 mm Lotus valve system

July 15, 2014 by MassDevice

European launch means physicians can now choose from three available valve sizes to match patient anatomy more precisely.

Press Release: Boston Scientific receives CE Mark for the new 25 mm Lotus valve system

Boston Scientific lands Euro approval for mid-size Lotus valve

July 15, 2014 by Arezu Sarvestani

Boston Scientific launches European sales of its 25 mm Lotus aortic valve, adding to the 23 mm and 27 mm valves already on the market.

Boston Scientific lands Euro approval for mid-size Lotus valve

Boston Scientific (NYSE:BSX) is heading straight to market with its 25 mm Lotus transcatheter aortic valve after winning CE Mark approval this week, the company announced.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Valve-in-valve surgery shows promise in new registry study

July 11, 2014 by Arezu Sarvestani

An new study shows that transcatheter aortic valve-in-valve implantation may be an important option for a growing population of patients with deteriorating bioprosthetic implants, but outcomes depend strongly on how the previous valve is failed.

Medtronic and Edwards implants show promise in valve-in-valve treatment

New research released this week provides more support for the use of transcatheter aortic valve-in-valve (VIV) implantation as a means of replacing previously implanted valves that have deteriorated over time.

More good news for Abbott's MitraClip in JACC study

July 11, 2014 by Arezu Sarvestani

Abbott's MitraClip implant reduces mitral regurgitation and improves quality of life at 1 year in high-risk patients, according to new study results from the Everest II clinical trial.

More good news for Abbott's MitraClip

High-risk patients with mitral regurgitation reduced their symptoms and reported better quality of life after treatment with Abbott's (NYSE:ABT) MitraClip implant, according to newly published results from the Everest II High Risk Registry.

Report: Stealthy Mvalve raises $15M from Boston Scientific

July 7, 2014 by Brad Perriello

Israeli heart valve maker Mvalve reportedly pulls in a $15 million investment from Boston Scientific in a deal that includes a $200 million buyout option.

Report: Stealthy Mvalve raises $15M from Boston Scientific

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp